Skip to content

Evaluation of treatment and long-term outcomes for recurrent hepatocellular carcinoma that was treated by surgery or radiofrequency ablation: a multicenter retrospective observational study (SURF-additional study)

Evaluation of treatment and long-term outcomes for recurrent hepatocellular carcinoma that was treated by surgery or radiofrequency ablation: a multicenter retrospective observational study (SURF-additional study) - Evaluation of recurrent hepatocellular carcinoma: a multicenter retrospective observational study (SURF-additional study)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000028292
Enrollment
1090
Registered
2017-07-20
Start date
2018-08-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

A primary hepatocellular carcinoma case with tumor foci numbering less than 3, each measuring 3 cm or less, Child-Pugh score of 7 or less, ages between 20 and 79 year, and indications for either surgical resection or radiofrequency ablation for the treatment

Interventions

None listed

Sponsors

Surgery vs. RFA (SURF) trial group
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) no preceded treatment 2) tumor foci numbering less than 3 and each measuring 3 cm or less exhibiting typical findings on dynamic CT 3) no extrahepatic lesion or vascular invasion 4) Child-Pugh score of 7 or less 5) tumors which can be curatively treated with both surgery and radiofrequency ablation 6) performance status 0-2 7) bone marrow function and hepatic/renal functions are well maintained a)White blood cell count: 2000-10000/mm3 b)Platelet count of 50000/mm3 or more c)Hemoglobin of 8.0g/dL or more d)Serum total bilirubin of 2.0mg/dL or less e)Prothronbin time of 50% or more f)Serum creatinine of 1.5mg/dL or less g)Blood urea nitrogen of 35mg/dL or less

Exclusion criteria

Exclusion criteria: 1) Double cancer or history of other malignancy within 5 years after diagnosis 2) History of myocardial infarction or unstable angina within 6 months prior to registration 3) Patient with interstitial pneumonia, pneumofibrosis, or severe lung emphysema 4) Patient who cannot undergo enhanced CT scan due to some reason such as allergy for iodized contrast media or renal dysfunction 5) Patient with psychiatric disorder or symptom 6) Pregnant patient or patient with possibility to be pregnant

Design outcomes

Primary

MeasureTime frame
Recurrence-free survival

Secondary

MeasureTime frame
1. Treatment selection after recurrence of hepatocellular carcinoma 2. Recurrence pattern 3. Tumor maker trend

Countries

Japan

Contacts

Public ContactYoshikuni Kawaguchi

The University of Tokyo Hospital Division of Hepato-Biliary-Pancreatic Surgery

yokawaguchi-tky@umin.ac.jp03-3815-5411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026